2022
Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2020
Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation
Tegel BR, Huber S, Savic LJ, Lin M, Gebauer B, Pollak J, Chapiro J. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation. Acta Radiologica 2020, 61: 1708-1716. PMID: 32216452, PMCID: PMC7529766, DOI: 10.1177/0284185120909964.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellContrast MediaDisease ProgressionFemaleHumansImaging, Three-DimensionalKidney NeoplasmsMaleMiddle AgedNeoplasm StagingRadiography, InterventionalRetrospective StudiesSensitivity and SpecificityTumor BurdenUltrasonography, InterventionalConceptsProgression-free survivalTotal tumor volumeRenal cell carcinomaCell carcinomaOdds ratioTumor volumeImaging biomarkersImage-guided thermal ablationPrognosis of patientsRENAL nephrometry scoreCox regression modelLargest tumor diameterLog-rank testKaplan-Meier plotsCross-sectional imagingSensitive imaging biomarkerMetastatic diseaseSecondary outcomesPrimary outcomeDistant metastasisNephrometry scoreTumor diameterOutcome parametersLesion vascularityTNM stage
2018
Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept. Journal Of Vascular And Interventional Radiology 2018, 29: 850-857.e1. PMID: 29548875, PMCID: PMC5970021, DOI: 10.1016/j.jvir.2018.01.769.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaDoxorubicinEthiodized OilFemaleHumansLiver NeoplasmsMachine LearningMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRetrospective StudiesSensitivity and SpecificityTreatment OutcomeConceptsTransarterial chemoembolizationHepatocellular carcinomaTreatment responseLogistic regressionClinical patient dataPatient dataIntra-arterial therapyQuantitative European AssociationMagnetic resonance imagingLiver criteriaBaseline imagingClinical variablesTumor responseTherapeutic featuresTreatment respondersBaseline MRClinical informationImaging variablesChemoembolizationTherapeutic outcomesResonance imagingResponse criteriaEuropean AssociationPatientsMR imaging
2016
Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma
Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. Journal Of Gastrointestinal Surgery 2016, 20: 2002-2009. PMID: 27714643, PMCID: PMC5106296, DOI: 10.1007/s11605-016-3285-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlpha-FetoproteinsAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPortal VeinRetrospective StudiesRisk FactorsSurvival RateTreatment OutcomeTumor BurdenVenous ThrombosisYoung AdultConceptsPortal vein tumor thrombosisAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaOverall survivalRisk scoreChild-Pugh A/BEastern Cooperative Oncology Group 0Child-Pugh B classLarge retrospective cohort studyRetrospective cohort studyAdvanced hepatocellular carcinomaStage hepatocellular carcinomaNumber of tumorsMedian OSCohort studyExtrahepatic metastasesSelect patientsTumor thrombosisImproved survivalPrognostic factorsTherapeutic recommendationsSurvival outcomesTumor sizeLonger survivalSorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF, Chapiro J. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. Clinical Advances In Hematology And Oncology 2016, 14: 585-7. PMID: 27487101.Peer-Reviewed Original Research
2014
Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers
Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers. Radiology 2014, 275: 438-47. PMID: 25531387, PMCID: PMC4409467, DOI: 10.1148/radiol.14141180.Peer-Reviewed Original ResearchConceptsUnresectable hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaTumor diameterHazard ratioTumor responseTumor volumeResponse rateCox proportional hazard ratiosStaging markersTumor response rateProportional hazard ratiosResponse Evaluation CriteriaSurvival of patientsKaplan-Meier analysisSingle-institution analysisBaseline magnetic resonance imagesHigh response rateInstitutional review boardOverall survivalLiver (EASL) guidelinesPatient cohortImaging markerRadiologic measurementsLarge lesionsRadiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis
Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis. Radiology 2014, 273: 746-758. PMID: 25028783, PMCID: PMC4263418, DOI: 10.1148/radiol.14140033.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaDiffusion Magnetic Resonance ImagingFemaleGadolinium DTPAHumansImage Interpretation, Computer-AssistedImaging, Three-DimensionalLiver NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesSoftwareTreatment OutcomeConceptsPathologic tumor necrosisHepatocellular carcinoma lesionsTumor necrosisTransarterial chemoembolizationCarcinoma lesionsRadiologic–pathologic correlation studyTumor tissueMagnetic Resonance Imaging AssessmentDiagnostic accuracyInstitutional review board-approved retrospective studyOrthotopic liver transplantationTotal tumor volumeDiffusion-weighted MR imagingApparent diffusion coefficient (ADC) mapsNecrotic tumor tissueArterial phase MR imagesDiffusion coefficient mapsLast MR examinationLiver transplantationSurgical resectionLiver criteriaPathologic examinationRetrospective studyPhase MR imagesHistopathologic examinationCombination of intra-arterial therapies and sorafenib: Is there a clinical benefit?
Chapiro J, Duran R, Geschwind JF. Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit? La Radiologia Medica 2014, 119: 476-482. PMID: 24894921, DOI: 10.1007/s11547-014-0413-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticEmbolization, TherapeuticHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsMicrospheresNeoplasm StagingNiacinamidePhenylurea CompoundsRadiography, InterventionalSorafenibSurvival RateConceptsIntra-arterial therapySurvival benefitIntroduction of sorafenibLoco-regional approachesAdvanced stage diseaseSignificant survival benefitUnresectable hepatocellular carcinomaLocal tumor controlTreatment of patientsSequence of administrationConventional systemic chemotherapyInternational clinical trialsOral monotherapySystemic chemotherapyExciting new optionsClinical outcomesTransarterial chemoembolizationClinical benefitSafety profileTumor controlClinical trialsHepatocellular carcinomaNovel agentsPotential biomarkersSystemic toxicityHave we finally found the ultimate staging system for HCC?
Chapiro J, Geschwind JF. Have we finally found the ultimate staging system for HCC? Nature Reviews Gastroenterology & Hepatology 2014, 11: 334-336. PMID: 24798199, DOI: 10.1038/nrgastro.2014.67.Peer-Reviewed Original Research
2013
Intraarterial therapies for primary liver cancer: state of the art
Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Review Of Anticancer Therapy 2013, 13: 1157-1167. PMID: 24099626, DOI: 10.1586/14737140.2013.845528.Peer-Reviewed Original ResearchConceptsPrimary liver cancerTreatment of patientsIntraarterial therapyHepatocellular carcinomaLiver cancerIntermediate-stage diseaseOfficial treatment guidelinesAvailable clinical evidenceEffective local tumor controlLocal tumor controlReduced systemic toxicityIntraarterial approachStage diseaseTransarterial chemoembolizationTreatment guidelinesClinical evidenceHepatic malignanciesTumor controlSystemic toxicityTherapyScientific rationalePatientsCancerTreatmentChemoembolization